0001706226-19-000004.txt : 20190327 0001706226-19-000004.hdr.sgml : 20190327 20190327160803 ACCESSION NUMBER: 0001706226-19-000004 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20190327 DATE AS OF CHANGE: 20190327 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: AYTU BIOSCIENCE, INC CENTRAL INDEX KEY: 0001385818 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 470883144 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-88813 FILM NUMBER: 19708477 BUSINESS ADDRESS: STREET 1: 373 INVERNESS PARKWAY STREET 2: SUITE 206 CITY: ENGLEWOOD STATE: CO ZIP: 80112 BUSINESS PHONE: (720) 437-6580 MAIL ADDRESS: STREET 1: 373 INVERNESS PARKWAY STREET 2: SUITE 206 CITY: ENGLEWOOD STATE: CO ZIP: 80112 FORMER COMPANY: FORMER CONFORMED NAME: AYTU BIOSCIENCE, INC. DATE OF NAME CHANGE: 20150609 FORMER COMPANY: FORMER CONFORMED NAME: Rosewind CORP DATE OF NAME CHANGE: 20070110 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Galileo Partners, LLC CENTRAL INDEX KEY: 0001706226 IRS NUMBER: 260275299 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 1063 GAYLEY AVE STREET 2: SECOND FLOOR CITY: LOS ANGELES STATE: CA ZIP: 90024 BUSINESS PHONE: 3102082225 MAIL ADDRESS: STREET 1: 1063 GAYLEY AVE STREET 2: SECOND FLOOR CITY: LOS ANGELES STATE: CA ZIP: 90024 SC 13G/A 1 20190326_AYTU_Ind.txt SCHEDULE 13-G AMENDMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* * Aytu BioScience, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 054754700 (CUSIP Number) March 20, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [_] Rule 13d-1(b) [X] Rule 13d-1(c) [_] Rule 13d-1(d) __________ *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 054754700 1. NAME OF REPORTING PERSONS Howard Deshong, III 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) [_] (b) [X] 3.SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION USA NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 400,000 6. SHARED VOTING POWER 218,283 7. SOLE DISPOSITIVE POWER 400,000 8. SHARED DISPOSITIVE POWER 218,283 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 618,283 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [_] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 4.9 12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) IN CUSIP No. 054754700 Item 1. (a). Name of Issuer: Aytu BioScience, Inc. (b). Address of issuer's principal executive offices: 373 Inverness Parkway, Suite 206 Englewood, Colorado 80112 Item 2. (a). Name of person filing: Howard Deshong, III (b). Address or principal business office or, if none, residence: Galileo Partners, LLC 1033 Gayley Ave, Ste 204 Los Angeles, CA 90024 (c). Citizenship: USA (d). Title of class of securities: Common Stock (e). CUSIP No.: 054754700 Item 3. If This Statement is filed pursuant to Section 240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a (a) [_] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). (b) [_] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). (c) [_] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). (d) [_] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). (e) [_] An investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E); (f) [_] An employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F); (g) [_] A parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G); (h) [_] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813); (i) [_] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) [_] A non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J); (k) [_] Group, in accordance with Section 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J), please specify the type of institution: Item 4. Ownership. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned: 618,283 (b) Percent of class: 4.9 (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote 400,000 (ii) Shared power to vote or to direct the vote 218,283 (iii) Sole power to dispose or to direct the disposition of 400,000 (iv) Shared power to dispose or to direct the disposition of 218,283 As calculated in accordance with Rule 13d-3 of the Securities Exchange Act of 1934, as amended, Howard Deshong, III (the Filer) beneficially owns 618,283 shares of the Issuer's common stock (Common Stock), representing approximately 4.9% of such class of shares outstanding. The Filer owns 250,904 shares, representing approximately 2%, of Common Stock outright; 89,500 of which the Filer owns directly and 161,404 that the filer owns in his capacities as managing member of the general partner of Galileo Partners Fund I, L.P., a Delaware limited partnership, and as trustee of the Howard C. Deshong, III Revocable Trust. The Filer also has the right to acquire a total of 367,379 Common Shares within 60 days due to his direct and indirect ownership of certain warrants and other convertible securities. Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X]. Item 6. Ownership of More Than Five Percent on Behalf of Another Person. Not applicable Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. Not applicable Item 8. Identification and Classification of Members of the Group. Not applicable Item 9. Notice of Dissolution of Group. Not applicable Item 10. Certification. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under s.240.14a-11. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. March 27, 2019 (Date) Howard Deshong, III By: /s/ Howard Deshong Name: Howard Deshong Title: Self The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature. Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent. Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).